Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure
Jean‐Jacques Body(Université Libre de Bruxelles), Karim Fizazi(Université de Lille), Julie R. Gralow(American Society of Clinical Oncology), Guenther G. Steger(Mount Vernon Hospital), Guozhi Gao(Amgen (United States)), Howard Yeh(Hospital de Santa Maria), Allan Lipton(National Cancer Centre Japan)
Cited by 120
Related Papers
Current and future burden of breast cancer: Global statistics for 2020 and 2040
|The Breast|2022|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study
|Journal of Clinical Oncology|2010|1.6k